ClinicalTrials.gg
RecruitingNCT07209371Updated Aug 17, 2026

Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance

A Phase 2 interventional study of Rifaximin and Biospecimen Collection in IgA Monoclonal Gammopathy of Undetermined Significance and Non-IgM Monoclonal Gammopathy of Undetermined Significance, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Fred Hutchinson Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States — 15 open to participants now, 18 under way, none of them phase 3. Monoclonal Gammopathy of Undetermined Significance · United States.

Planned enrollment
20th of 43
50 · median 40
Started
2026
with 1 other
Phase 2
17 of 76
2 open now
Primary completion
2028-05
later than 10 of 17 live
Registered
75th of 76
by date

Among the 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States, this one is the 20th largest by planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2026, is one of 17 in phase 2, reaches primary completion later than 10 of the 17 other live ones, and was the 75th registered.

Monoclonal Gammopathy of Undetermined Significance

102 studies on the registry are indexed under Monoclonal Gammopathy of Undetermined Significance; 28 are open to participants now.

Browse Monoclonal Gammopathy of Undetermined Significance studies →

Open to participants now

15 of the 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Monoclonal Gammopathy of Undetermined Significance studies recruiting now, 18 (90%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States, or all of them as a file.
02

Study summary

This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgG/IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgG/IgA MGUS.

Read the detailed description

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive rifaximin orally (PO) three times daily (TID) for 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.

ARM B: Patients undergo blood sample collection throughout the study.

After completion of study intervention, patients are followed up at 90 days.

03

Conditions studied

  • IgA Monoclonal Gammopathy of Undetermined Significance
  • Non-IgM Monoclonal Gammopathy of Undetermined Significance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Ability to understand and willingness to sign a written document. Legally authorized representatives may sign and give informed consent on behalf of potential study participants
  • Clinical diagnosis of IgG/IgA (non-IgM) monoclonal gammopathy of undetermined significance (MGUS) based on International Myeloma Working Group (IMWG)-2014 criteria (Rajkumar et al, Lancet Oncology, 2014). It is recognized that not all patients with clinical diagnosis of MGUS undergo bone marrow . Bone marrow biopsy confirmation will not be required if not clinically indicated per treating provider
  • Agree to use adequate

    • For women of : prior to study entry and for the duration of study participation
    • For men: prior to study entry, for the duration of study participation, and one month after completion of rifaximin administration (for men)
  • No antibiotic use in the preceding 2 weeks

Exclusion criteria

Exclusion Criteria:

  • Participants who are receiving other agents
  • Pregnant women
  • Known to rifaximin
  • Another concurrent requiring active therapy
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Arm A (Rifaximin)

    Patients receive rifaximin orally (PO) three times daily (TID) for 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.

    Drug: Rifaximin · Procedure: Biospecimen Collection

  • Other
    Arm B (No intervention)

    Patients undergo blood sample collection throughout the study.

    Procedure: Biospecimen Collection

Interventions

  • Given PO

    Also known as: Xifaxan

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

06

What researchers measure

Primary outcomes

  1. Overall response rate

    Defined as the proportion of patients with \> 25% decline in clonal Ig at any point within 90 days after the initiation of drug or no intervention. Logistic regression will be conducted to evaluate the association between endpoint of interest and treatment (Arm A versus \[vs\] B).

    Time frame: From the start of therapy, up to 90 days

Secondary outcomes

  1. Proportion of patients experiencing > grade 2 adverse events

    Logistic regression will be conducted to evaluate the association between endpoint of interest and treatment (Arm A vs B).

    Time frame: From the start of therapy, up to 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for May 2028, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Oct 7, 2025
StartActual
Jan 22, 2026
Primary completionEst.
May 1, 2028
CompletionEst.
May 1, 2028
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07209371
Collaborators
Rising Tide Foundation
Responsible party
Sponsor
First posted
Oct 7, 2025
Start date
Jan 22, 2026
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Madhav Dhodapkar, MBBS
Contact
mdhodapk@fredhutch.org
206-606-4888
Madhav Dhodapkar, MBBS
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion